Herbal medicine
Dosage
Major/Active Constituents
Key evidence
Potential AEs
Potential clinical use
Clinical advice
Ayahuasca ( Psychotria viridis plus Banisteriopsis caapi; or B. caapi plus Diplopterys cabrerana)
Variable dosage
MAOI:
Harmine, harmaline, and tetrahydroharmine
Dimethyltryptamine (DMT)
Upregulation of serotonin transporters; Research indicates anxiolytic effects and therapeutic potential to treat depression as well as substance dependence
Adverse reactions associated with “serotonin syndrome” have been reported when used in conjunction with SSRIs
Panic Disorder, Hoplessness,
Treatment for substance dependence (cocaine, crack cocaine, alcohol, tobacco)
Important to consider set and setting.
May have adverse effects if use is in close proximity to that of SSRIs, alcohol, hypnotics and sedatives. Future clinical research is warranted
In light of the widespread use of ayahuasca in a context of a changing world, there are important clinical considerations in terms of the potential adverse effects of ayahuasca use in combination with antidepressants, hypnotics and sedatives, and/or alcohol. It has been cautioned that the use of ayahuasca in conjunction with SSRI type antidepressants may result in “serotonin syndrome”due to the mechanistic action of both DMT as a 5-HT agonists and the inhibition of metabolic breakdown of serotonin transporters by MAOI [15, 39]. Further, it has been noted that the potential adverse effects from active metabolites may persist up to 5 weeks after discontinued use of SSRIs [39]; therefore, individuals employing the use of ayahuasca as a complementary approach to conventional psychotherapy and/or personal development should take the necessary precautions. In addition, in order to maximize harm reduction it is important for ayahuasca users to consider other potentially adverse interactions with the combination of ayahuasca and other drugs such as alcohol and certain foods. This said, there is perhaps wisdom in traditional dietary proscriptions employed by cultural practitioners (i.e., vegetalistas) who have long been aware of the potential adverse effects of the combination of ayahuasca and these substances – an area also in need of further investigation.
References
1.
2.
McKenna DJ, Luna LE, Towers GH. Biodynamic constituents in ayahuasca admixture plants. In: von Reis S, Schultes RE, editors. Ethnobotany: evolution of a discipline. Portland: Dioscorides Press; 1995.
3.
Luna LE. Indigenous and mestizo use of ayahuasca: an overview. In: Santos RE d, editor. The ethnopharmacology of ayahuasca. Trivandrum: Transworld Research Network, Kerala; 2011. p. 1–21.
4.
5.
McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenge. PharmacolTher. 2004;102(2):111–29.
6.
7.
Frecska E et al. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Trans. 2013;120(9):1295–303.CrossRef

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

